There has been a colossal rise in chronic diseases that leads to organ failure. Transplant diagnostics are tests performed to verify the compatibility between the recipient and donor before and after transplantation. With the increase in chronic diseases, the transplant diagnostic market is expected to grow at a faster rate in the near future. Market Research Future (MRFR)’s report on Global Transplant Diagnostics Market showcases that the market will grow at a CAGR of 7.2% during the forecast period (2017-2023) due to the increased demand for organ transplant surgeries.
There have been notable technological advancements in transplant diagnostics to provide better and advanced options for organ transplant. While the emerging regions such as Asia Pacific and Latin America and Middle East and Africa (LAMEA) holds possible opportunities, the market for transplant diagnostics in the developed countries is in a mature phase.
Global Transplant Diagnostics Market – Key Players
Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Becton Dickinson and Company (US), Abbott Laboratories Inc (US), CareDx (US), QIAGEN N.V. (Netherlands), Immucor, Inc. (US), GenDx (Netherlands), Omixon Ltd. (UK), bioMérieux S.A. (France), Illumina, Inc. (US), Immucor Transplant Diagnostics, Inc (US), Affymetrix, Inc (US), Linkage Biosciences (US)
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1324
In May 2018, CareDx, a U.S.-based molecular diagnostics company, has announced the signing of licensing and commercialization agreement with Illumina, a provider of next-generation sequencing solutions. CareDx is now the exclusive worldwide distributor of Illumina’s TruSight HLA v1 and v2 product lines which will be used for bone marrow transplantation diagnostic testing and solid organ transplantation diagnostic testing.
TAI Diagnostics which is US based company and develops non-invasive test to monitor patients’ health after they’ve got heart transplants, has scheduled to initiate selling their test early next year. They have generated about $13 million from their investors so far. The company is presently raising more money to supplement its $8.3 million Series A funding round. The extension could bring TAI’s total outside financing to $21 million, the startup’s test measures levels of cell-free DNA, genetic material released by the transplant recipient’s new heart that can enter the bloodstream, to assess whether they are in danger of rejecting the organ.
Thermo Fisher Scientific Acquires Linkage Bio: on July 2017 Thermo Fisher Scientific confirmed the company’s acquisition of Linkage Biosciences for an undisclosed amount, as a result of this acquisition Linkage Biosciences is now a part of Thermo Fisher’s transplant diagnostics business. The company based in South San Francisco, California. Benefits involved from the acquisition include a broader and deeper range of products, a continued commitment to innovation, and expanded support globally.
The business is extremely complementary to the company’s One Lambda tests, which regulate the compatibility of donors and recipients pre- and post-transplant. This acquisition further expands Thermo Fisher’s commitment of improving transplant patients’ quality of life over innovative high-quality products for the clinical and research segments of the transplant community.
Global Transplant Diagnostics Market – Segmentation
On the basis of technology, the diagnostics market has been segmented into non-molecular assay and molecular assay; wherein the molecular assay segment can be segregated into PCR based and segmented based. These techniques are used in monitoring and diagnosing diseases, decide therapies, and detecting risk for individual patients.
On the basis of components, the market has been segmented into instrument and equipment, reagents and consumables, and software and services. Continuous healthcare research is resulting in advanced treatments like organ transplants and stem cell therapy.
Based on application, the market can be categorized into research and diagnostic application; wherein the diagnostic application can be further segmented into histocompatibility testing, blood profiling, research applications and infectious disease diagnostics.
The transplant diagnostics market can be segmented on the basis of organ type into kidney, liver, heart, lung and pancreas. Kidney being the most widely transplanted organ, holding a share of 65 %. According to the National Key Foundation, around 3,000 new patients are added to the waiting list every month worldwide. Due to the over consumption of unhealthy diet and alcohol, there has been an increase in disease like renal diseases and diabetes, which in turn has contributed to the growth of the transplant diagnostics market.
Based on the method, the transplant diagnostics market is segmented into pre-transplant screening and post-transplant screening. These methods are used to identify donors which have or could be infected. This step is pivotal in preventing and alleviating the transmission of infectious diseases through organs.
On the basis of end users, the market is segmented into research laboratories, hospitals, transplant centers and commercial service providers.
Browse Complete 100 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/transplant-diagnostics-market-1324
Global Transplant Diagnostics Market – Regional Analysis
The Global Market for Transplant Diagnosis can be segmented into Europe, North America, Asia Pacific, and Rest-of-the-World (RoW). North America dominated the global transplant diagnostic market. The major factor driving the growth of the North America market is the increasing demand for diagnostic tools, advanced techniques, and healthcare expenditure.
While Europe is the second largest country in this market, Asia Pacific is expected to be the fastest growing country for this market during the forecast period due to its flourishing medical tourism in countries like India. The large patient pool vulnerable to chronic diseases is the biggest driving factor of the market.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar